Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TLR4 | O00206 | 1/20 | 0.57 |
| ▸ | TLR2 | O60603 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006523 | 1.00 | HTT (1.00) | HTTGAALMNASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL11180824 | 0.98 | HTT (0.97) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL8491329 | 0.89 | HTT (0.81) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL8491325 | 0.89 | HTT (0.81) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL8942449 | 0.89 | HTT (0.79) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL8942446 | 0.89 | HTT (0.79) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL9185939 | 0.86 | HTT (0.76) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL30584121 | 0.86 | HTT (0.76) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL9185934 | 0.86 | HTT (0.76) | HTTGAALMNASMN1; SMN2MAPT | |
| SCHEMBL11180817 | 0.86 | HTT (0.76) | HTTGAALMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458393-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166590-A1 | Microsomal triglyceride transfer protein | WETTERAU JOHN R (US) | 2003-09-04 | — | — | US | disclosed |
| WO-2003053443-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-07-03 | — | — | WO | disclosed |
| US-6492365-B1 | Microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| EP-0809622-B1 | ANTI-INFLAMMATORY BENZOIC ACID DERIVATIVES | SCIOS INC (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6066650-A | USEFUL FOR LOWERING SERUM LIPIDS AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| US-6034098-A | ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-5789197-A | GENETIC ENGINEERING | E. R. SQUIBB & SONS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0809622-A4 | ANTI-INFLAMMATORY BENZOIC ACID DERIVATIVES | SCIOS NOVA INC (US) | 1998-07-08 | — | — | EP | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0809622-A1 | ANTI-INFLAMMATORY BENZOIC ACID DERIVATIVES | SCIOS NOVA INC. (US) | 1997-12-03 | — | — | EP | disclosed |
| US-5595872-A | DNA SEQUENCES, CELLS AND EXPRESSION VECTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996025383-A1 | ANTI-INFLAMMATORY BENZOIC ACID DERIVATIVES | SCIOS NOVA INC. (US) | 1996-08-22 | — | — | WO | disclosed |
| US-5530157-A | NON-STEROID ANTIINFLAMMATORY DRUG | SCIOS NOVA INC. (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0643057-A1 | Inhibitors of microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166590-A1 | Microsomal triglyceride transfer protein | MTTP, CETP, HDLBP | HTT 1132/4885GAA 1215/4885LMNA 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.